Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04189952 · ClinicalTrials.gov registry record · Phase 2
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
A Phase 2 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04189952 is a Phase 2 study that was terminated before completion, run by University of Miami. The registered enrollment target is 2 participants.
The verdict
NCT04189952, a Phase 2 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to test a combination treatment of acalabrutunib when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) to evaluate if it will be able to improve durable responses and cure some patients.
Interventions
- DRUG Carboplatin
- DRUG Rituximab
- DRUG Etoposide
- DRUG Ifosfamide
- DRUG Acalabrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-09-22 |
| Est. Completion | 2022-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04189952
The ClinicalTrials.gov registry entry for NCT04189952 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT04189952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04189952 about?
NCT04189952 is a clinical study titled "Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma". The purpose of this study is to test a combination treatment of acalabrutunib when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) to evaluate if it will be able to improve durable responses and cure some patients.
What is the current status of trial NCT04189952?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-09-22. Estimated completion is 2022-03-01.
What interventions are being tested in trial NCT04189952?
The interventions under investigation include: Carboplatin (DRUG), Rituximab (DRUG), Etoposide (DRUG), Ifosfamide (DRUG), Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT04189952?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.